# Resource Summary Report

Generated by RRID on Aug 18, 2026

## pBABE-Src-Dasatinib-resistant

RRID:Addgene_26980
Type: Plasmid

### Proper Citation

RRID:Addgene_26980

### Plasmid Information

**URL:** http://www.addgene.org/26980

**Proper Citation:** RRID:Addgene_26980

**Insert Name:** c-Src

**Organism:** Gallus gallus

**Bacterial Resistance:** Ampicillin

**Defining Citation:** PMID:19573813

**Vector Backbone Description:** Backbone Marker:Addgene Plasmid 1765; Backbone Size:5558; Vector Backbone:pBABE-hygro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

**Comments:** Dasatinib resistant mutant. GenBank: V00402.1

**Plasmid Name:** pBABE-Src-Dasatinib-resistant

**Relevant Mutation:** T338I

**Record Creation Time:** 20220422T222121+0000

**Record Last Update:** 20260815T081258+0000

### Ratings and Alerts

No rating or validation information has been found for pBABE-Src-Dasatinib-resistant.

No alerts have been found for pBABE-Src-Dasatinib-resistant.

### Data and Source Information

**Source:** Addgene

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Elmadani M, et al. (2023) Dasatinib targets c-Src kinase in cardiotoxicity. Toxicology reports, 10, 521.

Lima NC, et al. (2020) Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. International journal of molecular sciences, 21(9).

Kessler BE, et al. (2019) Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene, 38(14), 2565.

Beadnell TC, et al. (2018) Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis, 7(2), 23.

Yeung CL, et al. (2013) Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene, 32(47), 5429.

Chan CM, et al. (2012) Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(13), 3580.